Gilead Sciences and Merck Collaboration to Develop Long-Acting HIV Treatment
Gilead Sciences (GILD) and Merck (MRK) announced the start of a Phase 2 clinical study evaluating an investigational, once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy.
From Gilead Sciences and Merck
Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences, said, “Partnerships and collaborations are critical to continuing the tremendous progress that has been made toward ending the HIV epidemic. This innovative research collaboration builds on the efforts of both companies to help make the end of the epidemic a reality through continued scientific advances in HIV. Initiating the trial represents an important step forward toward our goal of offering long-acting options that can help address the differentiated needs and preferences of the diverse range of people living with HIV.”